The results of this study indicate that rituximab is neither clinically effective nor cost-effective in this patient population.
No takes yet. Share an insight, caveat, or question.
Bowman et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: